Rigel Pharma (RIGL) Prices 13M Shares at $7.25
More News related to RIGL
- Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
- RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
More News related to Equity Offerings
- Shares of Brocade (BRCD) Outperforming as Oscar Gruss Upgrades to Buy
- Kinross (KGC) Jumps Higher as Gold Breaks $1,200, JPMorgan Upgrades to Overweight
- Raymond James Upgrades PSS World Medical (PSSI) to Outperform
- Capital One Southcoast Upgrades Penn Virginia (PVA) to Add; Turning Bullish After Data Release
- Raymond James Upgrades CPFL Energia S.A. (CPL) to Outperform
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a price to the public of $7.25 per share. All of the shares are being offered by Rigel. The underwriters have an option to purchase up to an additional 1,950,000 shares to cover over-allotments, if any. The offering is expected to close on September 22, 2009, subject to the satisfaction of customary closing conditions.
Credit Suisse Securities (USA) LLC is acting as the sole book-runner for the offering, with Oppenheimer & Co. Inc. and Thomas Weisel Partners LLC acting as co-managers.
Related Categories
Equity OfferingsStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
